Issue 11, 2013

Imidazolium salts as antifungal agents: activity against emerging yeast pathogens, without human leukocyte toxicity

Abstract

This study demonstrates the excellent in vitro antifungal activity profile of imidazolium ionic liquids (ILs) against species of opportunistic human mycoses. Several ILs were identified as more effective and less harmful than commercially available antifungal medications. Frequently, emerging yeast pathogens are resistant against commercial antifungal agents and, as a consequence, this class of imidazolium ILs represents a promising breakthrough in their treatment.

Graphical abstract: Imidazolium salts as antifungal agents: activity against emerging yeast pathogens, without human leukocyte toxicity

Supplementary files

Article information

Article type
Concise Article
Submitted
31 Jul 2013
Accepted
02 Sep 2013
First published
03 Sep 2013

Med. Chem. Commun., 2013,4, 1457-1460

Imidazolium salts as antifungal agents: activity against emerging yeast pathogens, without human leukocyte toxicity

H. S. Schrekker, R. K. Donato, A. M. Fuentefria, V. Bergamo, L. F. Oliveira and M. M. Machado, Med. Chem. Commun., 2013, 4, 1457 DOI: 10.1039/C3MD00222E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements